Home › Trials › NCT07929779
Clinical trial Recruiting at 1 site Observational Ages 18 to 50 Women only

Differential Granulosa Cell Transcriptome Profiling to Predict Ongoing Pregnancy

Official title: Differential Granulosa Cell Transcriptome Profiling as a Predictive Tool of Ongoing Pregnancy

Run by Vida Recoletas Sevilla · NCT07929779 · Data updated 2026-11-12

Aiming to see if differences in granulosa cell gene activity can predict ongoing pregnancy in IVF and oocyte donation with PGT-A.

Quick facts

Study typeObservational
Ages18 Years to 50 Years
SexWomen only
Enrollment100 (estimated)
SponsorVida Recoletas Sevilla
Academic / other
Drugs / interventionschemotherapy
Locations1 site (Seville, Sevilla)
StatusRecruiting
StartedDecember 10, 2025
Main results expectedFebruary 2028
Study endsJuly 2028
Registry record updatedNovember 10, 2026
Trial IDNCT07929779 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal participants are women aged 40-45 undergoing IVF with own fresh oocytes and PGT-A, oocyte donors aged 18-35, and oocyte recipients under 51 receiving fresh donor oocytes at VIDA Sevilla.

Probably not a fit

Patients whose granulosa cell transcriptomes do not reveal predictive patterns or who have non-representative biology may not benefit.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study examines whether transcriptome patterns in granulosa cells collected during IVF cycles can predict ongoing pregnancy outcomes. The study includes advanced maternal age patients, oocyte donors, and oocyte recipients at VIDA Sevilla, with cycles using fresh oocytes and PGT-A and embryo culture in Embryoscope. Data from gene expression profiles will be linked to pregnancy outcomes to identify potential biomarkers. No interventional treatment is described; the focus is on biomarker discovery and correlation with clinical results. Results could inform embryo selection and individualized treatment strategies if successful.

Why it matters

Potential benefit: If successful, this approach could improve the ability to select embryos with higher chances of ongoing pregnancy, potentially reducing IVF cycles and costs.

How similar studies have gone: Previous research in related fertility biomarker areas has shown promise, but this exact transcriptome-based predictive approach is still under investigation.

Who can join: the full rules

Show full inclusion / exclusion criteria 
INCLUSION CRITERIA:

* Advanced maternal age patients:

  * Between 40 and 45 years old, both inclusive
  * Patient at VIDA Sevilla
  * IVF cycle with own oocytes (fresh)
  * PGT-A cycle
  * Consent to perform embryo culture in Embryoscope
* Oocyte donors:

  * Between 18 and 35 years old
  * Being an oocyte donor accepted by VIDA Sevilla according to standard donor selection criteria at this clinic
* Oocyte recipients:

  * Patient at VIDA Sevilla
  * Younger than 51 years old
  * IVF cycle with fresh donor oocytes
  * Consent to perform embryo culture in Embryoscope
  * Matched donor already included in the study

EXCLUSION CRITERIA:

* Abnormal karyotype
* Reproductive tract anomalies
* Radio and chemotherapy treatments

Where it's running

  • Vida Recoletas Sevilla
    Seville, Sevilla, Spain     Recruiting

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov ↗ Find more trials like this →
Browse more
Infertility (IVF Patients) 23Oocyte Donation 2PGT-A 3Vida Recoletas Sevilla 3
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.